DiaMedica Receives Phase I/II Clinical Trial Regulatory Approval for DM-199 as a Potential Treatment for Diabetes

DiaMedica (TSX VENTURE:DMA), is pleased to announce it has received regulatory approval to commence an anticipated 76 subject Phase I/II clinical trial for DM-199. The clinical trial, to be conducted in the Netherlands, is designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of DM-199 in 36 healthy volunteers and in 40 T2D patients. Data from this trial will also support future DM-199 clinical trial regulatory filings for Type 1 and 2 diabetes and in other potential indications.

"We look forward to commencing the DM-199 clinical trial," stated Mr. Rick Pauls, Chairman & CEO, DiaMedica. "Based on pre-clinical results showing a novel dual mechanism of action (insulin sensitizer and insulin secretagogue) that improves glucose control and blood pressure, we have high hopes for this drug in improving the lives of diabetes patients."

Read more: DiaMedica ( DMA )

Anacor Pharmaceuticals Receives Significant Investment to Support Neglected Disease Research

Anacor Pharmaceuticals (ANAC) today announced that it has signed a research agreement with the Bill & Melinda Gates Foundation (the Gates Foundation) to discover drug candidates intended to treat two filarial worm diseases (onchocerciasis, or river blindness, and lymphatic filariasis, commonly known as elephantiasis) and tuberculosis (TB). Additionally, Anacor will create an expanded library of boron compounds to screen for additional potential drug candidates to treat neglected diseases and will provide access to the expanded library compounds for neglected disease research to the Gates Foundation, and others, including academic, governmental and other non-profit institutions or equivalent entities. Under the agreement, Gates Foundation will pay Anacor $17.7 million as well as invest $5 million in Anacor common stock.

Read more: Anacor Pharmaceuticals ( ANAC )

Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of $24.00 Per Share In Cash

Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that Valeant and Obagi Medical Products, Inc. (OMPI) have executed an amendment to their Agreement and Plan of Merger, dated March 19, 2013 . Pursuant to the amendment, Valeant increased its offer to acquire Obagi from $19.75 to $24.00 per share in cash.

The offer documents will be amended to reflect the new offer price of $24.00 per share. The expiration date of the tender offer will remain 12:00 midnight, New York City time, on April 23, 2013 . The tender offer is conditioned on the tender of a majority of Obagi's shares calculated on a diluted basis, as well as the receipt of certain regulatory approvals and other customary closing conditions.

Read more: Obagi Medical Products Inc ( OMPI )

Merz Pharma Group Makes Superior Proposal to Acquire Obagi Medical Products

Proposes to Acquire All of Obagi's Outstanding Common Stock for $22 Per Share in Cash Transaction Not Conditioned Upon Financing Or Due Diligence

In a letter to the Board of Directors of Obagi Medical Products, Inc. (OMPI) ("Obagi"), Merz Pharma Group ("Merz" or "the Company") today outlined a proposal to acquire all of the outstanding common stock of Obagi for $22 per share in cash.  This proposal represents a 58% premium to Obagi's closing share price on Thursday, March 14, 2013, the last trading day prior to the disclosure on Obagi's fourth quarter earnings call that Obagi had engaged a financial advisor to help explore "all opportunities." 

Read more: Obagi Medical Products Inc ( OMPI )

BioCryst Pharmaceuticals Provides Update Regarding Peramivir

BioCryst Pharmaceuticals, Inc. (BCRX) today announced that it received a preliminary comment letter from the U.S. Food & Drug Administration (FDA) that outlines a pathway by which BioCryst could file a New Drug Application (NDA) seeking regulatory approval of intravenous (i.v.) peramivir. The letter was sent in response to questions BioCryst submitted to the FDA in advance of an upcoming Type C regulatory meeting regarding i.v. peramivir. The FDA also suggested the Company request a pre-NDA meeting to reach agreement on a complete NDA submission and to address review issues identified in its preliminary comment letter.

Read more: BioCryst Pharmaceuticals Inc ( BCRX )